NCT01001702View on ClinicalTrials.gov

Oral Aripiprazole Open-Label Rollover Study

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole

Flexible dose between 5 mg and 30 mg Aripiprazole tablets.

Trial Locations (15)

Unknown

Study site, Buenos Aires

Study site, Mendoza

Study site, Split

Study site, Hyderabad

Study site, Ludhiana

Study site, Mumbai

Study site, Tamilnadu

Study site, Moscow

Study site, Rostov-on-Don

Study site, Saint Petersburg

Study site, Yaroslavl

Study site, Belgrade

Study site, Novi Sad

Study site, Kharkiv

Study site, Kiev

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01001702 - Oral Aripiprazole Open-Label Rollover Study | Biotech Hunter | Biotech Hunter